- Home
- ROIV vs EHC Comparison
ROIV vs EHC Comparison
Compare ROIV & EHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- EHC
- Stock Information
- Founded
- ROIV 2014
- EHC 1983
- Country
- ROIV United Kingdom
- EHC United States
- Employees
- ROIV N/A
- EHC N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- EHC Hospital/Nursing Management
- Sector
- ROIV Health Care
- EHC Health Care
- Exchange
- ROIV Nasdaq
- EHC Nasdaq
- Market Cap
- ROIV 8.8B
- EHC 10.2B
- IPO Year
- ROIV N/A
- EHC 1986
- Fundamental
- Price
- ROIV $11.57
- EHC $94.40
- Analyst Decision
- ROIV Strong Buy
- EHC Strong Buy
- Analyst Count
- ROIV 8
- EHC 8
- Target Price
- ROIV $17.93
- EHC $106.75
- AVG Volume (30 Days)
- ROIV 5.3M
- EHC 676.1K
- Earning Date
- ROIV 02-11-2025
- EHC 02-05-2025
- Dividend Yield
- ROIV N/A
- EHC 0.72%
- EPS Growth
- ROIV N/A
- EHC 18.07
- EPS
- ROIV 5.89
- EHC 4.14
- Revenue
- ROIV $129,128,999.00
- EHC $5,215,000,000.00
- Revenue This Year
- ROIV $15.98
- EHC $12.53
- Revenue Next Year
- ROIV N/A
- EHC $9.12
- P/E Ratio
- ROIV $2.06
- EHC $22.22
- Revenue Growth
- ROIV 145.68
- EHC 11.15
- 52 Week Low
- ROIV $9.69
- EHC $65.99
- 52 Week High
- ROIV $13.06
- EHC $104.55
- Technical
- Relative Strength Index (RSI)
- ROIV 41.56
- EHC 29.62
- Support Level
- ROIV $11.72
- EHC $100.78
- Resistance Level
- ROIV $12.22
- EHC $99.73
- Average True Range (ATR)
- ROIV 0.30
- EHC 1.97
- MACD
- ROIV -0.09
- EHC -1.01
- Stochastic Oscillator
- ROIV 15.24
- EHC 6.68
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.